At the IGTP TODAY

News

15/02/2018 - Research

IGTP researchers confirm the feasibility of immunotherapy in cells of the immune system of patients with type 1 diabetes

Researchers from the Immunology of Diabetes research group of the Germans Trias i Pujol Research Institute (IGTP) have confirmed, in human cells, that liposomes designed as immunotherapy for type 1 diabetes (T1D) are a valid strategy to arrest the autoimmune attack characteristic of this disease. They have done so in a preclinical study demonstrating the tolerogenic effect of these liposomes on cells of the immune system of patients with T1D. The results have been published in the journal Frontiers in Immunology.

Julia García Prado, new IGTP Scientific Director

Dr. García Prado, leader of the Viral Immune Evasion and Vacciones (VIRIEVAC) at the IrsiCaixa AIDS Research Institute will combine the new position with the leadership of her group, focused on the design of new strategies against HIV. Manel Puig, General Director of the IGTP, has presented the new organizational chart during the presentation of the Research Agenda 2018, together with the new challenges for the coming years.

Events